生物学的皮膚代替物市場-世界の産業規模、シェア、動向、機会、および予測、2018年-2028年

2022年、生物学的皮膚代替物市場の評価額は4億309万米ドルに達し、2028年までの年間平均成長率（CAGR）は8.08％と予測され、予測期間中に力強い成長が見込まれます。

この成長は、慢性創傷の発生率の上昇、老人人口の増加、再生医療技術の採用拡大など、いくつかの要因に起因しています。

生物学的皮膚代替物の市場は近年大きく拡大しており、この動向は予測期間を通じて持続すると予想されます。これらの代替皮膚は、熱傷、糖尿病性足潰瘍、外科的創傷など、多様な創傷の治療に応用されています。これらの代用品は、動物やヒトの組織から合成素材やそれらの組み合わせに至るまで、さまざまな素材から製造されています。

生物学的皮膚代替物市場の成長を促す顕著な要因は、慢性創傷の発生が増加していることであり、特に高齢化した層で広く見られます。慢性創傷は治療が難しく、適切な治癒を促進するために従来の創傷ケアアプローチを超える介入が必要となることが多いです。同時に、治癒効果を高め、治療費全体を抑えることを目的とした先進的な創傷治療製品に対する需要も高まっています。

さらに、生物学的皮膚代替物市場の拡大は、再生医療手法の普及によって促進されています。再生医療は、組織の再生と修復を促すために幹細胞やその他の生物学的実体を用います。再生医療の領域が進歩するにつれて、生物学的皮膚代替物の利用はより普及するものと思われます。

再生医療技術の採用増加

再生医療技術の採用拡大が、生物学的皮膚代替物の世界市場の拡大に大きな影響を与えています。再生医療は、幹細胞、成長因子、および組織の若返りと修復を刺激する他の生物学的成分の利用を包含します。

再生医療技術の普及に伴い、生物学的皮膚代替物の需要が急増することが予想されます。これらの製品は、多くの再生医療戦略において極めて重要な役割を果たしており、組織の活性化と修復のための構造的枠組みを提供するために頻繁に採用されています。

再生医療技術への関心の高まりは、この分野における研究開発への投資を増加させる原動力となっています。この原動力は技術革新を推進し、最終的には組織の若返りと修復のための優れたサポートを提供する、新規で強化された生物学的皮膚代替物の創造に結実しています。

再生医療技術の受け入れは、生物学的皮膚代替物の包括的な市場を拡大する態勢を整えています。この拡大の根拠は、これらの技術が慢性創傷や火傷から再建手術に至るまで、より広範な症状に対処するために活用されていることです。

生物学的皮膚代替物の利用を包含する再生医療技術の応用は、回復成果の向上と密接な相関関係があります。これらの製品は、組織の再生と修復を刺激し、患者の回復期間の短縮と機能的結果の改善に寄与することが立証されています。

さらに、生物学的皮膚代替物の使用を含む再生医療技術は、しばしば費用対効果に関連しています。組織の再生と修復を促進することにより、これらの製品は、皮膚移植や再建手術のような、より複雑で費用のかかる介入の必要性を軽減する可能性を秘めています。再生医療技術による牽引力の高まりは、世界の生物学的皮膚代替物市場の軌道を大きく形成しています。これらの技術がより広く統合されるにつれて、生物学的皮膚代替物に対する需要は増大し、それによって技術革新が促進され、これらの製品の包括的な市場の拡大が促進されると予想されます。

慢性創傷の増加

慢性創傷の急増は、生物学的皮膚代替物の世界市場拡大の極めて重要な決定要因です。慢性創傷とは、治癒に長期間を要する創傷のことで、世界的に重大な健康上の懸念となっています。慢性創傷は、糖尿病、循環障害、褥瘡などさまざまな要因によって生じる。慢性創傷に対処するために、生物学的皮膚代替物はますます注目を集めており、この課題に対する有望な治療法とみなされています。

慢性創傷の発生頻度が急増するにつれ、有効な代替治療に対する需要も高まっています。このような状況の中で、生物学的代用皮膚は実行可能な解決策として登場し、慢性創傷を管理するための革新的な手段を医療提供者が求める中、ヘルスケア領域で徐々に支持を集めつつあります。

技術の革新は、組織の再生と修復を促進する新規の強化された生物学的皮膚代替物の創出を後押ししています。このような変革的なプロセスが市場に革新を促し、慢性創傷への対応に高い効果を発揮する製品の処方につながっています。

慢性創傷の増加は、生物学的皮膚代替物の包括的な市場の拡大を促しています。これらの製品は、褥瘡、糖尿病性足潰瘍、静脈性下腿潰瘍など、ますます多様化する症状に対処するために利用されています。

生物学的皮膚代替物は、組織の再生と修復を促進する能力を実証しており、その結果、慢性創傷を抱える人々の治癒成績が改善されます。この治癒促進は、これらの病態と闘う患者の回復期間の短縮と生活の質の向上につながります。

さらに、慢性創傷の管理に生物学的皮膚代替物を利用することで、ヘルスケア提供者に経済的利益をもたらすことができます。これらの製品は、皮膚移植や再建手術のような侵襲的で費用のかかる手術の必要性を抑制する可能性を秘めています。

慢性創傷の罹患率の増加は、世界の生物学的皮膚代替物市場の進化を促進する最大の要因です。効果的な代替治療法の探求が勢いを増す中、ヘルスケアプロバイダーは生物学的皮膚代替物を有力な解決策としてますます注目するようになっています。

調査範囲

本レポートでは、世界の生物学的皮膚代替物市場を以下のカテゴリーに分類し、さらに業界動向についても詳述しています：

生物学的皮膚代替物市場、タイプ別

• ヒトドナー組織由来製品
• アセラー動物由来製品
• 生合成製品

生物学的皮膚代替物市場：用途別

• 慢性創傷
• 急性創傷

生物学的皮膚代替物市場：エンドユーザー別

• 病院・診療所
• 外来ケアセンター
• その他

競合情勢

• 企業プロファイル：生物学的皮膚代替物の世界市場における主要企業の詳細分析

利用可能なカスタマイズ：

• TechSci Research社は、与えられた市場データをもとに、企業固有のニーズに応じたカスタマイズを提供しています。レポートでは以下のカスタマイズが可能です：

企業情報

• 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 生物学的皮膚代替物の世界市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ別（ヒトドナー組織由来製品、アセラー動物由来製品、生合成製品）
  • 用途別（慢性創傷／急性創傷）
  • エンドユーザー別（病院・クリニック、外来医療センター、その他）
  • 地域別
  • 企業別（2022年）
• 製品マップ
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 地域別

第6章 北米の生物学的皮膚代替物市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 北米国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の生物学的皮膚代替物市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の生物学的皮膚代替物市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米生物学的皮膚代替物市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの生物学的皮膚代替物市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の展開
• 合併・買収
• 製品上市

第13章 生物学的皮膚代替物の世界市場SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Business Overview
• Type Offerings
• Recent Developments
• Key Personnel
• SWOT Analysis
  • Smith & Nephew, plc
  • 3M Company
  • Organogenesis, Inc.
  • Stratatech Corporation
  • Integra LifeSciences Corporation
  • Tissue Regenix Group
  • Mimedx Group

第16章 戦略的提言17.

In 2022, the biological skin substitutes market reached a valuation of USD 403.09 million, and it is poised to experience robust growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 8.08% through 2028. This growth can be attributed to several factors, including an escalating incidence of chronic wounds, an expanding geriatric population, and the growing adoption of regenerative medicine techniques.

The market for biological skin substitutes has witnessed significant expansion in recent years, and this trend is anticipated to persist throughout the forecast period. These substitutes find application in the treatment of a diverse array of wounds, encompassing burns, diabetic foot ulcers, and surgical wounds. They are fabricated from a variety of materials, ranging from animal and human tissues to synthetic materials and their combinations.

A prominent driver stimulating growth in the biological skin substitutes market is the escalating occurrence of chronic wounds, particularly prevalent in aging demographics. Chronic wounds are challenging to treat and frequently necessitate interventions exceeding conventional wound care approaches to facilitate proper healing. Concurrently, the demand for advanced wound care products is growing, aiming to enhance healing outcomes and curtail the overall cost of care.

Furthermore, the augmentation of the biological skin substitutes market is facilitated by the mounting embrace of regenerative medicine methodologies. Regenerative medicine employs stem cells and other biologic entities to prompt tissue regeneration and repair. As the domain of regenerative medicine advances, the utilization of biological skin substitutes is poised to become more prevalent.

The expansion of the biological skin substitutes market is also propelled by the introduction of novel products that promise improved healing outcomes and reduced risks of complications. For instance, select biological skin substitutes are engineered to mimic the structural and functional characteristics of natural skin. This emulation can enhance healing outcomes and diminish the likelihood of rejection or infection.

Nonetheless, the market faces challenges stemming from the substantial costs associated with these products. While biological skin substitutes offer tangible advantages over traditional wound care methods, their production costs can be considerable, and insurance coverage may not be universally available. Consequently, access to these products for patients who stand to benefit from them could be restricted.

In spite of these challenges, the trajectory for growth in the biological skin substitutes market remains optimistic. The growing demand for advanced wound care products is anticipated to expedite the development of innovative biological skin substitutes. Moreover, advancements in regenerative medicine and tissue engineering are anticipated to further propel market expansion.

Additionally, the rise in the application of regenerative medicine techniques is bolstering market growth. Regenerative medicine involves the utilization of stem cells and other biologic materials to incite tissue regeneration and repair. The growing popularity of regenerative medicine techniques in the treatment of chronic wounds has led to an increased demand for biological skin substitutes.

Furthermore, there is a growing preference for biological skin substitutes crafted from natural materials, including animal and human tissues. This preference is based on the lower risk of adverse reactions or rejection associated with these natural materials when compared to synthetic alternatives.

The development of pioneering technologies such as 3D printing and tissue engineering is driving innovation within the biological skin substitutes market. These technologies are enabling the creation of intricate and sophisticated skin substitutes that more closely replicate the structure and function of natural skin.

Recent years have witnessed a surge in product launches and developments in the realm of biological skin substitutes. This surge is fueled by the escalating demand for advanced wound care products and the increasing embrace of regenerative medicine techniques.

For instance, Organogenesis, Inc., a prominent provider of regenerative medicine solutions, introduced an updated version of its Apligraf product in 2021. Apligraf is a bi-layered living cell therapy employed in the treatment of diabetic foot ulcers and venous leg ulcers. The enhanced version boasts an extended shelf life and improved handling properties, facilitating ease of use for healthcare providers.

Furthermore, Mallinckrodt Pharmaceuticals, a specialized pharmaceutical company, secured FDA approval for its StrataGraft® product in 2020. StrataGraft® constitutes regenerative skin tissue used to address deep partial-thickness burns. It is created from human cells and designed to closely emulate the structure and functionality of natural skin. This product offers a fresh treatment avenue for patients afflicted with deep partial-thickness burns who may not be suitable candidates for autografting.

In a similar vein, MyOwn Medicines, a regenerative medicine entity, launched MyOwn Skin™ in 2021. MyOwn Skin™ is a personalized skin substitute crafted from the patient's own skin cells. This product is tailored for the treatment of chronic wounds, such as diabetic foot ulcers and venous leg ulcers. This personalized approach to skin substitutes is poised to enhance healing outcomes while reducing the potential for adverse reactions or rejection.

Increasing Adoption of Regenerative Medicine Techniques

The escalating adoption of regenerative medicine techniques is exerting a profound influence on the expansion of the worldwide market for biological skin substitutes. Regenerative medicine encompasses the utilization of stem cells, growth factors, and other biologic constituents to stimulate the rejuvenation and reparation of tissues.

As the incorporation of regenerative medicine techniques becomes more pervasive, there is an anticipated surge in the requisition for biological skin substitutes. These products play a pivotal role in numerous regenerative medicine strategies and are frequently employed to furnish a structural framework for the revitalization and mending of tissues.

The intensifying interest in regenerative medicine techniques is driving augmented investments in research and development within the field. This impetus is propelling innovation, ultimately culminating in the creation of novel and enhanced biological skin substitutes that offer superior support for tissue rejuvenation and restoration.

The embrace of regenerative medicine techniques is poised to broaden the comprehensive market for biological skin substitutes. The rationale behind this expansion is that these techniques are being harnessed to address a more extensive spectrum of conditions, spanning from chronic wounds and burns to reconstructive surgery.

The application of regenerative medicine techniques, which encompasses the utilization of biological skin substitutes, is closely correlated with enhanced recuperative outcomes. These products have been substantiated to stimulate tissue regeneration and repair, subsequently contributing to expedited recovery periods and ameliorated functional results for patients.

Moreover, regenerative medicine techniques, including the employment of biological skin substitutes, are often associated with cost-effectiveness. By stimulating tissue renewal and mending, these products have the potential to mitigate the necessity for more intricate and costly interventions, such as skin grafts and reconstructive surgery. The growing traction gained by regenerative medicine techniques is significantly shaping the trajectory of the global biological skin substitutes market. As these techniques become more widely integrated, the demand for biological skin substitutes is expected to amplify, thereby catalyzing innovation and fostering the expansion of the overarching market for these products.

Growing Incidences of Chronic Wounds

The escalating prevalence of chronic wounds is a pivotal determinant in shaping the expansion of the worldwide market for biological skin substitutes. Chronic wounds denote wounds that exhibit protracted healing periods and constitute a significant global health concern. They can arise due to an array of factors, encompassing diabetes, impaired circulation, and pressure ulcers. In addressing chronic wounds, biological skin substitutes are garnering increasing attention and are regarded as a promising remedy for this challenge.

As the frequency of chronic wounds surges, there is a concomitant rise in the demand for efficacious treatment alternatives. Within this context, biological skin substitutes emerge as a viable solution and are progressively gaining traction within healthcare domains as providers seek innovative avenues for managing chronic wounds.

Innovations in technology are propelling the creation of novel and enhanced biological skin substitutes that are adept at fostering tissue regeneration and repair. This transformative process is instigating innovation within the market and leading to the formulation of products that manifest heightened effectiveness in addressing chronic wounds.

The augmenting prevalence of chronic wounds is engendering an expansion of the overarching market for biological skin substitutes. These products are being harnessed to combat an increasingly diverse range of conditions, including pressure ulcers, diabetic foot ulcers, and venous leg ulcers.

Biological skin substitutes have demonstrated their capacity to stimulate tissue regeneration and repair, thereby culminating in ameliorated healing outcomes for individuals contending with chronic wounds. This enhancement translates into swifter recovery periods and an improved quality of life for patients grappling with these conditions.

Furthermore, the utilization of biological skin substitutes in the management of chronic wounds can yield economic benefits for healthcare providers. These products possess the potential to curtail the necessity for more invasive and costly interventions, such as skin grafts and reconstructive surgery.

The escalating incidence of chronic wounds constitutes a paramount influencer driving the evolution of the global biological skin substitutes market. As the quest for effective therapeutic alternatives gathers momentum, healthcare providers are increasingly looking to biological skin substitutes as a propitious solution.

Market Segmentation

Global Biological Skin Substitutes market can be segmented on the basis of type, application, end user and region. Based on type, the market can be further divided into human donor tissue-derived products, acellular animal derived products, and biosynthetic products. Based on application, the market is further bifurcated into chronic wounds and acute wounds. Based on end user, the market is divided into hospitals & clinics, ambulatory care centers, and others. On the basis of region, the market is divided into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

Smith & Nephew, plc, 3M Company, Organogenesis, Inc., Stratatech Corporation, Integra LifeSciences Corporation, Tissue Regenix Group, Mimedx Group are some of the leading players operating in the global Biological Skin Substitutes market.

Report Scope:

In this report, global Biological Skin Substitutes market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Biological Skin Substitutes Market, By Type:

• Human Donor Tissue-Derived Products
• Acellular Animal Derived Products
• Biosynthetic Products

Biological Skin Substitutes Market, By Application:

• Chronic Wounds
• Acute Wounds

Biological Skin Substitutes Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in Global Biological Skin Substitutes Market.

Available Customizations:

• With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biological Skin Substitutes Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Human Donor Tissue-Derived Products, Acellular Animal Derived Products, Biosynthetic Products)
  • 5.2.2. By Application (Chronic Wounds v/s Acute Wounds)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Product Map
  • 5.3.1. By Type
  • 5.3.2. By Application
  • 5.3.3. By End User
  • 5.3.4. By Region

6. North America Biological Skin Substitutes Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Biological Skin Substitutes Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Biological Skin Substitutes Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Biological Skin Substitutes Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Biological Skin Substitutes Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Biological Skin Substitutes Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Biological Skin Substitutes Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Biological Skin Substitutes Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Biological Skin Substitutes Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Biological Skin Substitutes Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Biological Skin Substitutes Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Biological Skin Substitutes Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Biological Skin Substitutes Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Biological Skin Substitutes Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Biological Skin Substitutes Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Biological Skin Substitutes Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Biological Skin Substitutes Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Biological Skin Substitutes Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Biological Skin Substitutes Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Biological Skin Substitutes Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Biological Skin Substitutes Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Biological Skin Substitutes Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Biological Skin Substitutes Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Biological Skin Substitutes Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Type Launches

13. Global Biological Skin Substitutes Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Types

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Type Offerings
• 15.3. Recent Developments
• 15.4. Key Personnel
• 15.5. SWOT Analysis
  • 15.5.1. Smith & Nephew, plc
  • 15.5.2. 3M Company
  • 15.5.3. Organogenesis, Inc.
  • 15.5.4. Stratatech Corporation
  • 15.5.5. Integra LifeSciences Corporation
  • 15.5.6. Tissue Regenix Group
  • 15.5.7. Mimedx Group

16. Strategic Recommendations17.